MapLight Therapeutics names Troy Cox as director

MapLight Therapeutics, Inc. filed an initial insider ownership report naming Troy Cox as a director of the company.

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. filed an initial insider ownership report naming Troy Cox as a director of the company. The Form 3 data in this excerpt shows no reported purchases, sales, exercises, gifts, or other insider transactions, indicating this is primarily an initial disclosure of his reporting status.

Key Figures

Buy transactions: 0 Sell transactions: 0 Derivative transactions: 0 +1 more

4 metrics

Buy transactions 0 Form 3 transaction summary for Troy Cox

Sell transactions 0 Form 3 transaction summary for Troy Cox

Derivative transactions 0 Form 3 derivative transaction count

Net buy/sell direction neutral Form 3 transaction summary

Key Terms

Form 3, director, insider transactions

3 terms

Form 3 regulatory

"filed an initial insider ownership report naming Troy Cox as a director"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

director financial

"identifying Troy Cox as a director and not an officer"

insider transactions financial

"shows no reported purchases, sales, exercises, gifts, or other insider transactions"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Troy Cox’s Form 3 filing mean for MapLight Therapeutics (MPLT)?

The Form 3 identifies Troy Cox as a director of MapLight Therapeutics. It serves as his initial insider ownership report, establishing him as a reporting person under SEC rules for future transactions.

Does the Troy Cox Form 3 for MPLT show any stock purchases or sales?

No purchases or sales appear in this Form 3 excerpt. The transaction summary lists zero buy and zero sell transactions, indicating no reported trading activity by Troy Cox in this specific filing.

What insider activity counts are reported in the MPLT Form 3 for Troy Cox?

The filing’s transaction summary shows zero buys, sells, exercises, gifts, tax withholdings, or restructurings. Net buy/sell direction is described as neutral, reflecting the absence of reported trading activity.

Is Troy Cox an officer or just a director at MapLight Therapeutics (MPLT)?

The Form 3 identifies Troy Cox as a director and not an officer of MapLight Therapeutics. The officer flag is set to zero and no officer title is listed in the data excerpt.

Does the Troy Cox Form 3 include any derivative securities for MPLT?

The derivative section in this Form 3 excerpt is empty. The derivative summary shows zero derivative transactions, indicating no options or similar instruments are reported here for Troy Cox.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 05:49 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cox Troy

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/23/2026

3. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)